98%
921
2 minutes
20
The viral quasispecies play an important role in pathogenesis. However, little is known about the nature of hepatitis B virus (HBV) quasispecies and its impact on the outcomes of chronic hepatitis B. Here, we characterized the bona fide quasispecies viral populations from 16 chronically infected patients by analyzing the near full-length viral genomes obtained by single genome sequencing. Follow-up plasma samples were collected from six patients after 6 months and from four patients after 3-5 years. We found that the viral population diversity levels were highly variable among these patients, depending on the status of the selection pressure. To further understand the host selection pressure over time, we compared viral sequences from different timepoints in 10 patients and found the hard selective sweep (HSS) at the whole genome level in three of them. This HSS was extremely strong and drove the highly diversified viral quasispecies into a distinct yet homogeneous viral population in each patient after 1-4 years of infection. The identical or nearly identical sequences in the homogeneous viral population indicate that they originate from a single infected source. Predominant and fixed mutations were observed in well-characterized T cell epitopes but not in known epitopes of neutralizing antibodies or N-linked glycosylation sites. Since HSS is strong enough to drive HBV quasispecies into near extinction and frequently occurs in chronic hepatitis B patients, this raises the hope for eliminating HBV from the last single reservoir through enhancing specific T cell immune responses targeting the highly selected homogeneous viruses.IMPORTANCEThe nature of bona fide hepatitis B virus (HBV) quasispecies and its potential impact on the outcomes of chronic hepatitis B are not well understood. Analysis of the high-quality near full-length HBV sequences from chronic hepatitis B patients identifies the strong hard selective sweep that can drive the viral quasispecies into a distinct yet highly homogeneous viral population. The nearly identical viral population suggests that all these viruses are from a single source. Predominant mutations were identified in known T cell epitopes but not in epitopes for neutralizing antibodies, indicating that the hard selective sweep is most likely driven by T cell selection pressure. These findings indicate that enhancement of specific T cell responses during chronic hepatitis B can easily eliminate the highly homogeneous viral population and serve as a promising approach to achieve the goal of a functional cure for chronic hepatitis B.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345218 | PMC |
http://dx.doi.org/10.1128/mbio.01113-25 | DOI Listing |
J Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFKaohsiung J Med Sci
September 2025
Hepatitis Research Center, College of Medicine; Center for Metabolic Disorders and Obesity; Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver condition that can progress to severe complications such as metabolic dysfunction-associated steatohepatitis (MASH). Despite its growing burden, there are no reliable non-invasive biomarkers for tracking disease progression. In this study, we established a murine MASLD/MASH model using a high-fat diet and chemical (CCl) induction.
View Article and Find Full Text PDFAnn Gastroenterol Surg
September 2025
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima University Hiroshima Japan.
Background: Liver fibrosis is a key factor in the progression of chronic liver diseases, including viral hepatitis and metabolic dysfunction-associated steatotic liver disease. If untreated, fibrosis can progress to cirrhosis, increasing the risk of liver cancer or failure. This study evaluates the Fibrosis (FIB)-3 index, a novel marker free from age-related biases, for predicting liver fibrosis and 5-year outcomes in hepatocellular carcinoma (HCC) patients undergoing hepatectomy.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Department of Obstetrics and Gynecology, the Second Hospital of Nanjing, and Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Hepatitis B virus (HBV) infection is a serious public health concern worldwide, especially during pregnancy due to the associated health risks for the mother and fetus. This study aimed to explore the relationship between alanine aminotransferase (ALT) levels, age and HBV DNA levels in pregnant women with chronic HBV infection. Our cohort study included 1743 pregnant women with HBV who gave birth from January 2021 to June 2024.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
To assess the efficacy and safety of the Velpatasvir (VEL)/Sofosbuvir (SOF) with or without Ribavirin (RBV) in treating patients with decompensated hepatitis C cirrhosis. We searched multiple databases for studies published from October 2010 to September 2024. Outcomes of interest were sustained viral response at 12 weeks (SVR12) and the safety of VEL/SOF with and without RBV regimens in patients with decompensated hepatitis C virus (HCV) cirrhosis.
View Article and Find Full Text PDF